FDA Approval Is Sought for TAR-200 in BCG-Unresponsive High-Risk NMIBC With CIS
An NDA has been submitted to the FDA seeking the approval of TAR-200 for BCG-unresponsive high-risk NMIBC with CIS, with or without papillary tumors.
Related Articles
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Response Depth in High-Risk Smoldering Multiple Myeloma May Predict Outcomes
Complete response rate strongly correlated with lower SLiM-CRAB incidence and biochemical progression in those with high-risk smoldering multiple myeloma.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
ESMO Deep Dive: Lung Cancer – Precision Oncology 2025
This ESMO Webinar Series is available to all ESMO Members.
2025 BSH Paediatric Special Interest Group Meeting
2025 BSH Paediatric Special Interest Group Meeting
Discussions on the future of cancer care at the World Economic Forum in 2025
There is an urgent need to globally strengthen cancer-care systems considering projections that cancer cases will substantially increase during the coming years, said global leaders…
Effects of US withdrawal from WHO on cancer care in Africa
On Jan 20, 2025, US President Donald Trump issued an executive order to withdraw the USA from WHO. The move could jeopardise public health care…
Looking forward to ISAL 2025
Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, shares her excitement for the 19th International Symposium on Acute Leukemias (ISALXIX), taking place on March 16-19,…
Olutasidenib + azacitidine in patients with IDH1-mutated R/R AML: Pooled analysis from a phase I/II trial
We summarize results of a pooled analysis from a multicenter, open-label, phase I/II trial published by Cortes et al. evaluating the effectiveness and tolerability of…
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial
For patients aged 50 years or older and at 3 years post diagnosis, less frequent mammograms were non-inferior compared with annual mammograms for breast cancer-specific…
